Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1136/jitc-2020-000587
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2020
Authors
Publisher
BMJ